Phone: 888-558-5227

651-644-8424

888-558-7329 Fax:

Email: getinfo@lktlabs.com Web: lktlabs.com

Product Information

Product ID 06845

CAS No. 96829-58-2

Chemical Name N-Formyl-L-leucine(1S)-1-[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl]-

dodecyl ester

Synonym Orlipastat, Xenical

Formula C₂₉H₅₃NO₅ Formula Wt. 495.73 Melting Point 43°C Purity ≥98%

Solubility Soluble in DMSO or ethanol.

Pricing and Availability

Bulk quanitites available upon request

Product ID	Size	List Price
O6845	100 mg	\$135.00
O6845	500 mg	\$360.70
O6845	1 g	\$601.20

Store Temp 4°C

Ship Temp Ambient

Description Orlistat is an inhibitor of fatty acid synthase that is clinically administered for its anti-obesity benefits. Orlistat is often used as a weight loss aid, although it also exhibits anticancer chemotherapeutic activity. In animal models of T cell lymphoma, orlistat increases levels of ROS, NO, caspase 3, Bcl-2, and p53, increasing life span and inhibiting tumor growth; similar results are found in animal models of colorectal carcinoma.

References Kant S, Kumar A, Singh SM. Tumor growth retardation and chemosensitizing action of fatty acid synthase inhibitor or listat on T cell lymphoma: implication of reconstituted tumor microenvironment and multidrug resistance phenotype. Biochim Biophys Acta. 2014 Jan;1840(1):294-302. PMID: 24060750.

> Chuang HY, Chang YF, Hwang JJ. Antitumor effect of orlistat, a fatty acid synthase inhibitor, is via activation of caspase-3 on human colorectal carcinoma-bearing animal. Biomed Pharmacother. 2011 Jul;65(4):286-92. PMID: 21723078.

Halpern A, Pepe RB, Monegaglia AP, et al. Efficacy and tolerability of the association of sibutramine and orlistat for six months in overweight and obese patients. J Obes. 2010;2010. pii: 602537. PMID: 20871858.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.